Sivik Global Healthcare LLC Buys 30,000 Shares of Abbott Laboratories $ABT

Posted by Francis Steltz on Oct 13th, 2026

Sivik Global Healthcare LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 120.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,000 shares of the healthcare product maker’s stock after purchasing an additional 30,000 shares during the quarter. Abbott Laboratories accounts for approximately 3.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 11th largest holding. Sivik Global Healthcare LLC’s holdings in Abbott Laboratories were worth $5,436,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its position in shares of Abbott Laboratories by 14.1% in the third quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock valued at $8,339,000 after purchasing an additional 10,431 shares during the period. Juncture Wealth Strategies LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $658,000. Aureus Asset Management LLC raised its position in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Thompson Investment Management Inc. lifted its stake in Abbott Laboratories by 786.0% in the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after buying an additional 12,474 shares in the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new position in Abbott Laboratories in the 2nd quarter valued at about $4,889,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.4%

Shares of ABT stock traded up $0.45 on Tuesday, reaching $102.27. 3,354,660 shares of the stock were exchanged, compared to its average volume of 11,274,359. The company has a market capitalization of $176.97 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 1.85 and a beta of 0.59. The business’s 50 day moving average price is $106.14 and its 200 day moving average price is $98.29. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $133.34.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Analyst Ratings Changes

Several equities research analysts have commented on ABT shares. Barclays initiated coverage on Abbott Laboratories in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. BTIG Research raised their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, TD Cowen reiterated a “buy” rating and set a $135.00 price target on shares of Abbott Laboratories in a report on Tuesday, September 8th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $118.88.

Check Out Our Latest Report on ABT

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.